Top

Published in:

01-04-2014 | Research

In-Vitro and In-Vivo Imaging of Prostate Tumor Using NaYF₄: Yb, Er Up-Converting Nanoparticles

Authors: Yongjiang Yu, Tao Huang, Yu Wu, Xiaorong Ma, Guopeng Yu, Jun Qi

Published in: Pathology & Oncology Research | Issue 2/2014

Abstract

The aim of this study was to investigate the feasibility of prostate tumor bioimaging both in vitro and in vivo using an upconversion fluorophore, NaYF₄: Yb, Er nanoparticles. Luminescent signals of human prostate cancer cells (CWR22R and LNCaP) labeled with NaYF₄: Yb, Er nanoparticles were detected by laser scanning confocal microscope, while Cy3 or FITC was used as control probe. Mouse-human prostate cancer model was developed by subcutaneously injecting the CWR22R cells into BALB/c nude mice to investigate the in-vivo imaging properties of NaYF₄:Yb, Er nanoparticles. Both CWR22R and LNCaP cells could phagocytose NaYF₄:Yb, Er nanoparticles in vitro, and the cellular uptake of CWR22R cells was much higher than that of LNCaP cells (95.42 ± 3.47 % vs. 51.63 ± 6.43 %), which made us choose the former for the further study. CWR22R cells pre-labeled with NaYF₄:Yb, Er nanoparticles showed no obvious decrease of fluorescence intensity (P > 0.05) after light exposure, while the fluorescence intensity of Cy3 or FITC labeled cells decreased rapidly with prolonged bleaching (P < 0.05). Furthermore, the in-vivo results showed that the prostate cancer cells pre-labeled with or without NaYF₄:Yb, Er nanoparticles formed tumors 4 weeks after injection, and the tumor length-diameter of the nanoparticle group and the control group was (10.3 ± 2.0) mm and (9.8 ± 2.5) mm, respectively. Significant upconversion fluorescence signals were observed in the tumors of the nanoparticle group when being excited at 980 nm by a NIR laser. In summary, the results suggest that as an intensive fluorescence imaging label agent, NaYF₄:Yb, Er nanoparticles possess unique features and can be used for imaging prostate tumor cells both in vitro and in vivo by phagocytosis.

Ren J, Wang F, Wei G, Yang Y, Liu Y, Wei M, Huan Y, Larson AC, Zhang Z (2012) MRl of prostate cancer antigen expression for diagnosis and immunotherapy. PLoS One 7(6):e38350. doi:10.1371/journal.pone.0038350 PubMedCentralPubMedCrossRef

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300. doi:10.3322/caac.20073caac.20073 PubMedCrossRef

Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G (2008) The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 15(1):3866–3871PubMedCentralPubMed

Abdolahi M, Shahbazi-Gahrouei D, Laurent S, Sermeus C, Firozian F, Allen BJ, Boutry S, Muller RN (2013) Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging 8(2):175–184. doi:10.1002/cmmi.1514 PubMedCrossRef

Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5(3):161–171. doi:10.1038/nrc1566 PubMedCrossRef

Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760. doi:10.1038/nnano.2007.387 PubMedCrossRef

He F, Yang P, Wang D, Li C, Niu N, Gai S, Zhang M (2011) Preparation and up-conversion luminescence of hollow La2O3:Ln (Ln = Yb/Er, Yb/Ho) microspheres. Langmuir 27(9):5616–5623. doi:10.1021/la200506q PubMedCrossRef

Chatterjee DK, Rufaihah AJ, Zhang Y (2008) Upconversion fluorescence imaging of cells and small animals using lanthanide doped nanocrystals. Biomaterials 29(7):937–943. doi:10.1016/j.biomaterials.2007.10.051 PubMedCrossRef

Idris NM, Li Z, Ye L, Sim EK, Mahendran R, Ho PC, Zhang Y (2009) Tracking transplanted cells in live animal using upconversion fluorescent nanoparticles. Biomaterials 30(28):5104–5113. doi:10.1016/j.biomaterials.2009.05.062 PubMedCrossRef

10.

Yu M, Li F, Chen Z, Hu H, Zhan C, Yang H, Huang C (2009) Laser scanning up-conversion luminescence microscopy for imaging cells labeled with rare-earth nanophosphors. Anal Chem 81(3):930–935. doi:10.1021/ac802072d10.1021/ac802072d PubMedCrossRef

11.

Xiong L, Chen Z, Tian Q, Cao T, Xu C, Li F (2009) High contrast upconversion luminescence targeted imaging in vivo using peptide-labeled nanophosphors. Anal Chem 81(21):8687–8694. doi:10.1021/ac901960d PubMedCrossRef

12.

Wang C, Tao H, Cheng L, Liu Z (2011) Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles. Biomaterials 32(26):6145–6154. doi:10.1016/j.biomaterials.2011.05.007 PubMed

13.

Mader HS, Kele P, Saleh SM, Wolfbeis OS (2010) Upconverting luminescent nanoparticles for use in bioconjugation and bioimaging. Curr Opin Chem Biol 14(5):582–596. doi:10.1016/j.cbpa.2010.08.014 PubMedCrossRef

14.

Lin M, Zhao Y, Wang S, Liu M, Duan Z, Chen Y, Li F, Xu F, Lu T (2012) Recent advances in synthesis and surface modification of lanthanide-doped upconversion nanoparticles for biomedical applications. Biotechnol Adv 30(6):1551–1561. doi:10.1016/j.biotechadv.2012.04.009 PubMedCrossRef

15.

Soukka T, Rantanen T, Kuningas K (2008) Photon upconversion in homogeneous fluorescence-based bioanalytical assays. Ann N Y Acad Sci 1130:188–200. doi:10.1196/annals.1430.0271130/1/188 PubMedCrossRef

16.

Wang F, Liu X (2009) Recent advances in the chemistry of lanthanide-doped upconversion nanocrystals. Chem Soc Rev 38(4):976–989. doi:10.1039/b809132n PubMedCrossRef

17.

Lim SF, Ryu WS, Austin RH (2010) Particle size dependence of the dynamic photophysical properties of NaYF4:Yb, Er nanocrystals. Opt Express 18(3):2309–2316. doi:10.1364/OE.18.002309195128 PubMedCrossRef

18.

Cao T, Yang T, Gao Y, Yang Y, Hu H, Li F (2010) Water-soluble NaYF <sub> 4 </sub>: Yb/Er upconversion nanophosphors: synthesis, characteristics and application in bioimaging. Inorg Chem Commun 13(3):392–394CrossRef

19.

Wang M, Mi CC, Wang WX, Liu CH, Wu YF, Xu ZR, Mao CB, Xu SK (2009) Immunolabeling and NIR-excited fluorescent imaging of HeLa cells by using NaYF(4):Yb, Er upconversion nanoparticles. ACS Nano 3(6):1580–1586. doi:10.1021/nn900491j PubMedCrossRef

20.

Egerer K, Roggenbuck D, Hiemann R, Weyer MG, Buttner T, Radau B, Krause R, Lehmann B, Feist E, Burmester GR (2010) Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests. Arthritis Res Ther 12(2):R40. doi:10.1186/ar2949ar2949 PubMedCentralPubMedCrossRef

21.

Chan KH, Kwan JS, Ho PW, Ho JW, Chu AC, Ramsden DB (2010) Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflammation 7:50. doi:10.1186/1742-2094-7-501742-2094-7-50 PubMedCentralPubMedCrossRef

22.

Xiong L, Yu M, Cheng M, Zhang M, Zhang X, Xu C, Li F (2009) A photostable fluorescent probe for targeted imaging of tumour cells possessing integrin alpha(v)beta(3). Mol Biosyst 5(3):241–243. doi:10.1039/b820576k PubMedCrossRef

23.

Yu M, Zhao Q, Shi L, Li F, Zhou Z, Yang H, Yi T, Huang C (2008) Cationic iridium(III) complexes for phosphorescence staining in the cytoplasm of living cells. Chem Commun (Camb) 18:2115–2117. doi:10.1039/b800939b CrossRef

24.

Smith AM, Duan H, Mohs AM, Nie S (2008) Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev 60(11):1226–1240. doi:10.1016/j.addr.2008.03.015 PubMedCentralPubMedCrossRef

25.

Xiong LQ, Chen ZG, Yu MX, Li FY, Liu C, Huang CH (2009) Synthesis, characterization, and in vivo targeted imaging of amine-functionalized rare-earth up-converting nanophosphors. Biomaterials 30(29):5592–5600. doi:10.1016/j.biomaterials.2009.06.015 PubMedCrossRef

26.

Lim SF, Riehn R, Ryu WS, Khanarian N, Tung CK, Tank D, Austin RH (2006) In vivo and scanning electron microscopy imaging of up-converting nanophosphors in Caenorhabditis elegans. Nano Lett 6(2):169–174. doi:10.1021/nl0519175 PubMedCrossRef

27.

Zhang P, Rogelj S, Nguyen K, Wheeler D (2006) Design of a highly sensitive and specific nucleotide sensor based on photon upconverting particles. J Am Chem Soc 128(38):12410–12411. doi:10.1021/ja0644024 PubMedCrossRef

28.

Chen Z, Chen H, Hu H, Yu M, Li F, Zhang Q, Zhou Z, Yi T, Huang C (2008) Versatile synthesis strategy for carboxylic acid-functionalized upconverting nanophosphors as biological labels. J Am Chem Soc 130(10):3023–3029. doi:10.1021/ja076151k PubMedCrossRef

29.

Bruchez M Jr, Moronne M, Gin P, Weiss S, Alivisatos AP (1998) Semiconductor nanocrystals as fluorescent biological labels. Science 281(5385):2013–2016PubMedCrossRef

30.

Wu X, Gong S, Roy-Burman P, Lee P, Culig Z (2013) Current mouse and cell models in prostate cancer research. Endocr Relat Cancer. doi:10.1530/ERC-12-0285

31.

Bocci G, Di Paolo A, Danesi R (2013) The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis. doi:10.1007/s10456-013-9334-0 PubMedCentralPubMed

32.

Wang HZ, Wang HY, Liang RQ, Ruan KC (2004) Detection of tumor marker CA125 in ovarian carcinoma using quantum dots. Acta Biochim Biophys Sin (Shanghai) 36(10):681–686CrossRef

33.

Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, Ge N, Peale F, Bruchez MP (2003) Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21(1):41–46. doi:10.1038/nbt764nbt764 PubMedCrossRef

34.

Ness JM, Akhtar RS, Latham CB, Roth KA (2003) Combined tyramide signal amplification and quantum dots for sensitive and photostable immunofluorescence detection. J Histochem Cytochem 51(8):981–987PubMedCrossRef

Title: In-Vitro and In-Vivo Imaging of Prostate Tumor Using NaYF4: Yb, Er Up-Converting Nanoparticles
Authors: Yongjiang Yu
Tao Huang
Yu Wu
Xiaorong Ma
Guopeng Yu
Jun Qi
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-013-9700-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Research on the Typical miRNA and Target Genes in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus Cancer with DNA Microarray

The TPO/c-MPL Pathway in the Bone Marrow may Protect Leukemia Cells from Chemotherapy in AML Patients

Expression of Cyclophilin A in Gastric Adenocarcinoma Patients and Its Inverse Association with Local Relapses and Distant Metastasis

Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas

Clinicopathological Sex- Related Relevance of Musashi1 mRNA Expression in Esophageal Squamous Cell Carcinoma Patients

Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas of the Gallbladder: An Immunohistochemistry Study of Prognostic Markers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer